In the News 3 Things to Expect from the CDRH in 2016 and 2017 FDA Programs How a New FDA Program Helps Pharmaceuticals Implement Emerging Technology FDA Warning Letters 10 Key Elements of an FDA 483 Response Regulations FDA Group’s Larry Stevens Finds Major Issues With Sen. Cruz’s FDA Overhaul Proposal FDA Warning Letters The 3 Ingredients of an FDA-Compliant Tweet Process 3 Parts of a Comprehensive GCP Quality Audit Process How to Choose the Right Expedited FDA Approval Program Compliance Consulting The FDA Group President Nick Capman Interviewed at Vistage Executive Summit 2015 Process Laboratory Developed Tests: Issues and Anticipated Regulations